Dr. Erik Allen Imel, MD

Dr. Imel practices at IU Health Methodist Hospital in Indianapolis, Indiana, part of Indiana University Health.

Dr. Imel's NPI, 1326178971, was assigned on March 6, 2007. Dr. Imel graduated from University Of Cincinnati College Of Medicine in 1999. Dr. Imel's Indiana license number on file is 01057842A.

Dr. Imel's primary practice is IU Health Methodist Hospital, at 1701 N Senate Blvd, Indianapolis, IN 46202 in Marion County. The practice phone is (317) 962-2000.

Dr. Imel's primary practice is IU Health Methodist Hospital in Indianapolis, Indiana, part of Indiana University Health. Dr. Imel is also affiliated with IU Health Bloomington Hospital. The medical group on file is IU Health Medical Group. Dmand AI also links Dr. Imel to 3 more group practices and clinics, 2 medical groups and 1 behavioral health center, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Imel practices, 6 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Imel's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dr. Imel is board certified in endocrinology, diabetes and metabolism by the American Board of Internal Medicine. Dmand AI has Dr. Imel's licenses on file in 2 states: Indiana and New York.

Dmand AI lists enlarged thyroid, osteoporosis and underactive thyroid among the conditions Dr. Imel treats.

CMS data shows 86 Medicare services from Dr. Imel across 3 procedure codes in 2024, for 59 Medicare patients. Medicare paid $3,680 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 59 Medicare patients who saw Dr. Imel in 2024. The largest group is 65 to 74, with 25 patients. 61% of them have high blood pressure, and 54% have high cholesterol. 27% are also on Medicaid. Their average risk score is 1.58, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Imel's median patient age at 34, with 60% women.

In 2024, Dr. Imel wrote 325 Medicare Part D claims for 46 patients. 64% of them were for generic drugs. CMS names the drug for 227 of them, across 8 drugs with 11 or more claims each, at $1,097,213 in total drug cost. In 2023, CMS named 234 claims across 7 drugs.

Dr. Imel accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 76 papers to Dr. Imel, published from 2005 to 2024. 2015 was the busiest year, with 5. The most frequent topics are Familial Hypophosphatemic Rickets, Fibroblast Growth Factor-23 and Fibroblast Growth Factors. Dr. Imel has published most often in J Clin Endocrinol Metab. Dr. Imel's most frequent co-authors are Michael J. Econs, MD, Suzanne Jan De Beur, MD and Kathryn M. Dahir, MD.

Dmand AI links Dr. Imel to 4 clinical trials. 1 is still active or recruiting. Conditions studied include Familial Hypophosphatemic Rickets, Hypoparathyroidism and Hypophosphatemic Rickets, Autosomal Dominant. Indiana University sponsors the most, 2.

CMS Open Payments shows 93 general payments to Dr. Imel from 11 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 92% of the total. Kyowa Kirin, Inc. paid the most, $26,982. It also lists 19 research payments totaling $44,017 from 2024 to 2025.

Dr. Imel graduated from University Of Cincinnati College Of Medicine in 1999. Dr. Imel is a member of ENDO.

Dr. Imel is in network with 16 carriers, including Aetna, Elevance and United Healthcare. PPO plans come from the most carriers, 10. Check the plan with the practice before a visit.